Market Intelligence, Clinical Progress, and High-Purity Reagents for Primary Ciliary Dyskinesia (PCD) and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DNAH5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DNAH5 Recombinant Domain Proteins (N-terminal / C-terminal fragments) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View DNAH5 Products |
| Gene Delivery | DNAH5 Promise-ORF / Lentivirus Truncated functional domains or full-length ORF for stable cell lines. |
View DNAH5 Products |
| Benchmark Ab | Anti-DNAH5 Recombinant Antibody Recombinant positive control for immunofluorescence and Western Blot. |
View DNAH5 Products |
| Validator | DNAH5 siRNA Set For knockdown verification in ciliated cell models. |
View DNAH5 Products |
| Related Target A | DNAI1 Outer dynein arm intermediate chain 1; critical co-complex partner mutated in PCD. |
View DNAI1 Products |
| Related Target B | DNAH11 Dynein axonemal heavy chain 11; complementary target for comprehensive outer dynein arm diagnostic panels. |
View DNAH11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Massive Protein size (~529 kDa) hindering full-length expression | Domain-specific recombinant fragments (e.g., N-term, C-term) with Theoretical MW verified by SDS-PAGE |
| High-specificity diagnostic antibody validation | Sequence-verified antigen fragments for precise epitope mapping and counter-screening |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live DNAH5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DNAH5 therapeutics is intensifying, with major players shifting focus from traditional symptom management to genetic therapies including mRNA-LNP delivery and gene editing. As first-generation ciliary therapies reach the clinic, the next wave of R&D is targeting restoring outer dynein arm (ODA) assembly in airway epithelial cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| mRNA-LNP Therapy | ReCode Therapeutics, Translate Bio / Sanofi | Primary Ciliary Dyskinesia (PCD) | Functional expression rescue assays (Need DNAH5 Lentivirus and Domain-specific Antibodies) |
| Diagnostic Antibodies | Academic Consortia, Diagnostic Developers | PCD Screening / Nasal Biopsy | Epitope-specific antigens for IHC/IF validation (Need High-Purity Recombinant Domains) |
| Small Molecule Chaperones | Vertex Pharmaceuticals, Spirovant | Ciliopathies / Cystic Fibrosis overlap | Protein interaction assays (Need Sequence-Verified DNAH5/DNAI1 complexes) |